Recording a net profit for the year of SAR 358.85 million.
Completion of all legal and financial studies related to the fundamental deal with Dallah Healthcare Company.
Helping subsidiaries' companies list their shares on the financial market.
Approval by the company’s shareholders at the Extraordinary General Assembly meeting held on 28 September 2025 to extinguish the share premium amounting to SAR 59.76 million against accumulated losses.
Amendment of Article Three of the company’s bylaws relating to the company’s objectives, including the investment of the company’s funds in shares and other securities.
The company seeks to reformulate its investment strategy following the completion of the key transaction related to the sale of the subsidiaries, with a focus on diversifying investments, enhancing sustainable growth, and improving financial performance efficiency, in line with shareholders’ aspirations and with the aim of achieving attractive long-term returns.
During the coming phase, the company is working on further developing its investment direction in light of its new structure after the exclusion of the medical services segment during 2025.
The company is also focusing on studying available investment opportunities and expanding its investments in shares, securities, and other investment assets in a manner that supports sustainable growth and maximizes shareholder value.
Completion of the transaction for the sale of the company’s full stakes in Al-Ahsa Medical Services Company and Al-Salam Medical Services Company during 2025.
Extinguishment of the share premium amounting to SAR 59.76 million against accumulated losses.
Amendment of the company’s objectives in the bylaws to allow the investment of the company’s funds in shares and other securities.
Reduction of non-controlling interests to zero as a result of the disposal of the subsidiaries during 2025.